Form 8-K - Current report:
SEC Accession No. 0001193125-25-067076
Filing Date
2025-03-28
Accepted
2025-03-28 16:09:11
Documents
13
Period of Report
2025-03-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d928462d8k.htm   iXBRL 8-K 29860
  Complete submission text file 0001193125-25-067076.txt   154054

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA me-20250324.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE me-20250324_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE me-20250324_pre.xml EX-101.PRE 11260
16 EXTRACTED XBRL INSTANCE DOCUMENT d928462d8k_htm.xml XML 3682
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 25786054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)